The aim: to evaluate the effectiveness, safety and benefits of using the respiratory-intestinal probiotic Baktoblis+Lacto in the complex therapy of children with acute bacterial tonsillitis (ABT). Object and methods of the study. The study included 50 patients with ABT aged 4 to 18 years: boys — 23, girls — 27, the average age was 7.5±0.4. The main group (n=25) — patients received standard antibiotic therapy (according to the modern clinical protocol) and the respiratory-intestinal probiotic Baktoblis+Lacto for 20 days. The control group (n=25) — patients received only standard antibiotic therapy (according to the modern clinical protocol) without a probiotic. Results. When analyzing the dynamics of clinical symptoms during the treatment period, a comparable regression was observed in both clinical groups, however, patients in the main group had a faster tendency for pain and halitosis to regress. The microbiological study found that the use of Baktoblis+Lacto contributes to the reliable restoration of the microbiocenosis of the palatine tonsils by reducing the number of pathogenic and conditionally pathogenic microflora, as well as preserving with a pronounced tendency to increase the number of resident normoflora. In children in the main group, the frequency of episodes of acute tonsillitis during the year of observation decreased almost 3 times compared to patients in the control group, and the number of necessary courses of treatment with antibiotics — 5 times (p<0.05). Conclusion. The obtained results of the clinical study indicate a pronounced positive effect of the use of the respiratory-intestinal probiotic Baktoblis+Lacto on the clinical course of ABT disease in children and the state of their restored microbiocenosis, and also contributes to a 3-fold reduction in repeated episodes of ABT during the year.